Effects of Rosiglitazone/Metformin Fixed-Dose Combination Therapy and Metformin Monotherapy on Serum Vaspin, Adiponectin and IL-6 Levels in Drug-Naïve Patients with Type 2 Diabetes

Abstract

Objective: Vaspin, adiponectin and interleukin-6 (IL-6) constitute novel adipose-tissue derivatives, known as adipokines, which mediate insulin resistance. The aim of the present study was to evaluate the effects of metformin and rosiglitazone on serum levels of those novel adipokines in drug-naïve patients with type 2 diabetes mellitus (T2DM).

Methods: 140 patients with T2DM, already treated with diet, but without adequate glycemic control (HbA1c>7%), were randomly assigned to: RSG+MET group, (n=70): Combination therapy with fixed dose of 4 mg rosiglitazone plus 500 mg metformin. MET group, (n=70): Half-maximum dose of metformin monotherapy (1 700 mg/day). Before and after 6-month treatment, body-mass index (BMI), blood pressure (BP), fat-mass, fasting plasma glucose (FPG), HbA1c, insulin resistance indexes (HOMA-IR, insulin), lipids, high-sensitivity CRP (hsCRP), vaspin, adiponectin, and interleukin-6 (IL-6) were measured.

Results: Glucose regulation and insulin resistance were equivalently improved from baseline within both groups (p<0.05). There was a considerable amelioration of hsCRP, WBC, adiponectin, IL-6, systolic and diastolic BP with rosiglitazone/metformin combined treatment as compared to baseline (p<0.05) and MET group (p<0.05). In contrast, metformin monotherapy significantly reduced BMI (p<0.001), total-cholesterol (p=0.012) and LDL (p=0.020) levels compared to RSG+MET group. Importantly, serum vaspin concentration was equivalently decreased from baseline in both RSG+MET (−0.96±0.75 ng/ml, p<0.001) and MET (−0.92±0.57 ng/ml, p=0.001) group. The aforementioned vaspin changes correlated with changes in WHR, HbA1c, FPG, HOMA-IR, insulin, IL-6 (only in the RSG+MET group) and fat-mass. In standard multiple regression analysis, FPG, HbA1c, HOMA-IR and insulin remained independent determinants of serum vaspin levels changes (R²=0.836, p=0.004).

Conclusions: Both rosiglitazone/metformin combination therapy and metformin monotherapy decreased serum vaspin levels through glucose and insulin sensitivity regulation, while they exerted differential effects on adiponectin, IL-6 and other cardiovascular risk factors in drug-naïve patients with T2DM.

Key words

rosiglitazone - metformin - vaspin - adiponectin - IL-6 - type 2 diabetes - drug-naïve

References

• 1 Andreadis EA, Katsanou PM, Georgiopoulos DX. et al . The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects – The Carmos Study.  Exp Clin Endocrinol Diabetes. 2009;  117 175-180
• 2 Buse JB, Ginsberg HN, Bakris GL. et al . American Heart Association; American Diabetes Association: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.  Diabetes Care. 2007;  30 162-172
• 3 Ceriello A. Thiazolidinediones as anti-inflammatory and anti-atherogenic agents.  Diabetes Metab Res Rev. 2008;  24 14-26
• 4 Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects.  Diabetes Rev. 1998;  6 89-131
• 5 Derosa G, Tinelli C, Maffioli P. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes.  Diabetes Obes Metab. 2009;  11 1091-1099
• 6 Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.  Ann Intern Med. 2007;  147 578-581
• 7 Eder K, Baffy N, Falus A. et al . The major inflammatory mediator interleukin-6 and obesity.  Inflamm Res. 2009;  58 727-736
• 8 Fruhbeck G. Overview of adipose tissue and its role in obesity and metabolic disorders.  Methods Mol Biol. 2008;  456 1-22
• 9 Giles TD, Sander GE. Effects of thiazolidinediones on blood pressure.  Curr Hypertens Rep. 2007;  9 332-337
• 10 Gulcelik NE, Karakaya J, Gedik A. et al . Serum vaspin levels in type 2 diabetic women in relation to microvascular complications.  Eur J Endocrinol. 2009;  160 65-70
• 11 Hamann A, Garcia-Puig J, Paul G. et al . Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controlled on metformin alone.  Exp Clin Endocrinol Diabetes. 2008;  116 6-13
• 12 Han SH, Sakuma I, Shin EK. et al . Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies.  Prog Cardiovasc Dis. 2009;  52 126-140
• 13 Hemmingsen B, Lund SS, Wetterslev J. et al . Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes.  Eur J Endocrinol.. 2009;  161 1-9
• 14 Hida K, Wada J, Eguchi J. et al . Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity.  Proc Natl Acad Sci USA. 2005;  102 10610-10615
• 15 Home PD, Pocock SJ, Beck-Nielsen H. et al . RECORD Study Team: Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.  Lancet. 2009;  373 2125-2135
• 16 Hsiao FY, Huang WF, Wen YW. et al . Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan.  Drug Saf. 2009;  32 675-690
• 17 Ibáñez L, López-Bermejo A, Díaz M. et al . Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months.  Clin Endocrinol (Oxf). 2009;  71 351-357
• 18 Jakubowska J, Bohdanowicz-Pawlak A, Milewicz A. et al . Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment.  Gynecol Endocrinol. 2008;  24 378-384
• 19 Kadoglou NP, Gerasimidis T, Golemati S. et al . The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability.  J Vasc Surg. 2008;  47 55-62
• 20 Kadoglou NP, Iliadis F, Angelopoulou N. et al . Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus.  Diabet Med. 2008;  25 333-340
• 21 Kadoglou NP, Tsanikidis H, Kapelouzou A. et al . Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.  Metabolism. 2010;  59 373-379
• 22 Kim HJ, Kang ES, Kim DJ. et al . Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.  Clin Endocrinol (Oxf). 2007;  66 282-289
• 23 Kim HJ, Kim SK, Shim WS. et al . Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus.  Diabetes Res Clin Pract. 2008;  81 42-49
• 24 Klöting N, Berndt J, Kralisch S. et al . Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes.  Biochem Biophys Res Commun. 2006;  339 430-436
• 25 Matthaei S, Bierwirth R, Fritsche A. et al . Medical antihyperglycaemic treatment of type 2 diabetes mellitus. Update of the evidence-based guideline of the German Diabetes Association.  Exp Clin Endocrinol Diabetes. 2009;  117 522-557
• 26 Molavi B, Rassouli N, Bagwe S. et al . A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications.  Vasc Health Risk Manag. 2007;  3 967-973
• 27 Monami M, Marchionni N, Mannucci E. Winners and losers at the rosiglitazone gamble A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone.  Diabetes Res Clin Pract. 2008;  82 48-57
• 28 Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.  N Engl J Med. 2007;  356 1-15
• 29 Pfützner A, Marx N, Walcher D. et al . Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease.  Clin Lab. 2008;  54 237-241
• 30 Redinger RN. Fat storage and the biology of energy expenditure.  Transl Res. 2009;  154 52-60
• 31 Ríos-Vázquez R, Marzoa-Rivas R, Gil-Ortega I. et al . Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.  Am J Cardiovasc Drugs. 2006;  6 231-242
• 32 Rizos CV, Liberopoulos EN, Mikhailidis DP. et al . Pleiotropic effects of thiazolidinediones.  Expert Opin Pharmacother. 2008;  9 1087-1108
• 33 Sam S, Haffner S, Davidson MH. et al . Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes.  Diabetes Care. 2009;  32 932-937
• 34 Schernthaner G. Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors.  Int J Clin Pract. 2009;  63 912-929
• 35 Seeger J, Ziegelmeier M, Bachmann A. et al . Serum levels of the adipokine vaspin in relation to metabolic and renal parameters.  J Clin Endocrinol Metab. 2008;  93 247-251
• 36 Selvin E, Bolen S, Yeh HC. et al . Cardiovascular outcomes in trials of oral diabetes medications: a systematic review.  Arch Intern Med. 2008;  168 2070-2080
• 37 Tan BK, Heutling D, Chen J. et al . Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance.  Diabetes. 2008;  57 1501-1507
• 38 von Eynatten M, Liu D, Hock C. et al . Urinary adiponectin excretion: a novel marker for vascular damage in type 2.  Diabetes. 2009;  58 2093-2099
• 39 Yang T, Soodvilai S. Renal and vascular mechanisms of thiazolidinedione-induced fluid retention.  PPAR Res. 2008;  2008 963414
• 40 Youn BS, Klöting N, Kratzsch J. et al . Serum vaspin concentrations in human obesity and type 2 diabetes.  Diabetes. 2008;  57 372-327

Correspondence